Investigating the Role of Von Willebrand Factor in Blood Vessel Formation
Impact of Von Willebrand Factor and Its Multimers on Angiogenesis
This study looks at how a protein related to von Willebrand disease affects blood vessel formation in people with the condition to better understand their bleeding issues.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 90 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Nantes University Hospital Academic / other |
| Locations | 1 site (Nantes) |
| Trial ID | NCT04810702 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on understanding the expression of proteins involved in angiogenesis among 70 patients diagnosed with von Willebrand disease. The researchers aim to identify potential biomarkers and explore the relationship between these proteins, the distribution of multimers, and the clinical manifestations of the disease, particularly bleeding associated with angiodysplasias. By analyzing blood samples, the study seeks to enhance the understanding of how von Willebrand factor influences vascular health in affected individuals.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with von Willebrand disease confirmed by genetic analysis.
Not a fit: Patients with conditions that interfere with angiogenesis or those receiving treatments affecting blood coagulation may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and therapeutic strategies for patients with von Willebrand disease.
How similar studies have performed: While there is ongoing research into the role of von Willebrand factor in various conditions, this specific approach to studying its impact on angiogenesis is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: For patients: * Patient with von Willebrand disease proven by genetic analysis of the VWF gene. * Lack of treatment that could interfere with angiogenesis. * Patient informed by an information note sent to his home, with the possibility of objecting to the use of his blood samples in the context of research. For the control: * Patient with a normal coagulation report * Absence of abnormal hemorrhagic symptoms * Lack of notion of angiodysplasia. * Lack of treatment that could interfere with angiogenesis. * Patient informed by an information note sent to his home, with the possibility of objecting to the use of his blood samples in the context of research. Exclusion Criteria: * Patient under guardianship or curatorship. * Pregnant and lactating women. * Blood transfusion or treatment with von Willebrand factor concentrates less than 7 days old. * Treatment which may interfere with angiogenesis.
Where this trial is running
Nantes
- CHU de Nantes — Nantes, France (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.